Myasthenia Gravis and ThymomaPeripheral Neuropathies and DisordersAmyotrophic Lateral Sclerosis ResearchParkinson's Disease and Spinal DisordersGenetic Neurodegenerative Diseases
Publications
166
Citations
8,006
Est. group size
—
Recurring co-author estimate
Active years
45
Publishing since 1982
Publication cadence
Publications per year over the last 10 years — averaging 4.4/year recently
Recent publications
- Response to Rozanolixizumab Across Treatment Cycles in Patients With Generalized Myasthenia Gravis: A Post Hoc Analysis of Final Pooled Phase Three Data (P9-9.004)
Neurology · 2026
- Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series
The Lancet · 2025
- Whole-genome bisulfite sequencing of cell-free DNA unveils age-dependent and ALS-associated methylation alterations
Cell & Bioscience · 2025
- Effect of Rozanolixizumab on Ocular Symptoms in Patients with Generalized Myasthenia Gravis: A Post Hoc Item-level Analysis of Myasthenia Gravis-specific Outcomes in MycarinG (P1-11.006)
Neurology · 2025
- Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
European Journal of Neurology · 2025
- Correlation Between MG Symptoms PRO and Existing MG-Specific Outcome Scores in the Phase 3 MycarinG Study: Post Hoc Analysis (P1-11.026)
Neurology · 2025
- 3595 Effect of rozanolixizumab on ocular symptoms in generalised myasthenia gravis: <i>post hoc</i> item-level analysis of myasthenia gravis-specific outcomes in MycarinG
2025
- Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Journal of Neurology · 2025
- Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial
Muscle & Nerve · 2024
- Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study
Therapeutic Advances in Neurological Disorders · 2024
- Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-label Extension Studies (P10-11.003)
Neurology · 2024
- Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis (P10-11.005)
Neurology · 2024
- 2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a<i>post hoc</i>analysis
2024
- 01O Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis
Neuromuscular Disorders · 2024
- 21088. RESPUESTA A ROZANOLIXIZUMAB A TRAVÉS DE CICLOS DE TRATAMIENTO EN PACIENTES CON MIASTENIA GRAVIS GENERALIZADA: UN ANÁLISIS POST HOC
Neurology Perspectives · 2024
Publishes in
- Neurology×16
- Muscle & Nerve×4
- IUScholarWorks (Indiana University)×2
- New England Journal of Medicine×1
- The Lancet Neurology×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile